Across TCGA pan-cancer cohorts, DGCR8 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DGCR8 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher DGCR8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DGCR8 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
CESC, UCEC, and PRAD are the cancer types where DGCR8 Mutation most reproducibly stratifies survival.